India-US partnership critical to vaccinating world against COVID-19: Envoy Taranjit Singh Sandhu

He was speaking at a virtual roundtable on “Vaccine for All” during which eminent participants including Bill Gates discussed how safe, affordable and reliable vaccines can be delivered to all

The partnership between India and the US in the healthcare sector is critical to vaccinating the world against the coronavirus, India’s Ambassador here Taranjit Singh Sandhu said. Observing that vaccinating the world must be the priority strategy against the COVID-19 pandemic, Sandhu on Tuesday said the world’s map of vaccinations presents a story of disparities with the under-developed countries, including those in Africa, lagging at 10 per cent or below.

Sandhu was speaking at a virtual roundtable on “Vaccine for All” during which eminent participants including Bill Gates discussed how safe, affordable and reliable vaccines can be delivered to all.In addition to Gates, Co-Chair and Trustee of the Bill and Melinda Gates Foundation; other eminent participants to the roundtable were Dr V K Paul, member of Niti Aayog and Dr Soumya Swaminathan, Chief Scientist at the World Health Organisation (WHO); Proffessor Peter Jay Hotez, from Baylor College of Medicine in Houston and Congressman Dwight Evans, Member Ways & Means Committee and Subcommittee on Health.

“Lots of lessons learnt during this pandemic to inform future R&D (research and development) and vaccine development for all infectious diseases. Appreciate having been part of these discussions,” Swaminathan said.In his welcome address, Sandhu said that in the process of vaccination for all, India–US healthcare partnership is critical for three reasons.

First, there has been robust and long-standing collaboration between India and the US in the health sector including in vaccines. The bilateral Vaccine Action Programme (VAP) resulted in development of ROTAVAC – vaccine against Rotavirus.This vaccine developed by an Indian company (Bharat Biotech) significantly brought down the costs. The established linkages between Indian and US institutions, and researchers augur well in the fight against COVID-19, he said.Second, the convergences between India and the US are strong.

“I only need to point you to the intensive engagements last year at bilateral, Quad and multilateral levels. Prime Minister (Narendra) Modi’s visit to the US, Bilateral Summit with President (Joe) Biden and the Quad Summit were significant, substantive and comprehensive. The Quad Vaccines Initiative is on track to roll out this year on its promise of 1 billion J & J vaccines manufactured by India’s Biological E,” Sandhu said.And finally, India and the US have unique synergies that can be leveraged, he noted.

The cutting-edge technology and research leadership of the US and capabilities of India as the world’s largest vaccine manufacturer can be combined for producing affordable vaccines, he said.“This is already happening – look at the collaboration by Baylor College of Medicine and India’s BioE to produce patent free and logistically easier Corbevax or the collaboration between Novavax and Serum Institute of India to produce Covovax. India has already given emergency use approval for these vaccines.

“In my interactions with the US administration, Congress, industry and people, the enthusiasm to tap into our synergies for global good has been tremendous. Indeed, this work must be continued. As Prime Minister Modi said ‘India stands ready to work with the world to end the pandemic’,” Sandhu added.